Logo Logo

Publications by Reinacher-Schick, A.

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date
Number of items: 7.

Journal article

Haas, M.; Siveke, J. T.; Schenk, M.; Lerch, M. M.; Caca, K.; Freiberg-Richter, J.; Fischer von Weikersthal, L.; Kullmann, F.; Reinacher-Schick, A.; Fuchs, M.; Kanzler, S.; Kunzmann, V.; Ettrich, T. J.; Kruger, S.; Westphalen, C. B.; Held, S.; Heinemann, V.; Böck, S. (2018): Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'. In: European Journal of Cancer, Vol. 94: pp. 95-103

Geissler, M.; Martens, U.; Knorrenschild, J. R.; Greeve, J.; Florschütz, A.; Tannapfel, A.; Mönnich, H.; Ettrich, T.; Kanzler, S.; Büchner-Steudel, P.; Heinemann, V.; Held, S.; Reinacher-Schick, A.; Hebart, H.; Atzpodien, J.; Egger, M.; Lindig, U.; Müller, C. (2017): mFOLFOXIRI plus Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIO-KRK0109). In: Oncology Research and Treatment, Vol. 40: p. 123

Haas, M.; Böck, S.; Siveke, J. T.; Schenk, M.; Lerch, M.; Caca, K.; Freiberg-Richter, J.; Fischer von Weikersthal, L.; Kullmann, F.; Reinacher-Schick, A.; Fuchs, M.; Ettrich, T. J.; Kanzler, S.; Kunzmann, V.; Kruger, S.; Westphalen, C. B.; Held, S.; Heinemann, V. (2017): Efficacy of gemcitabine plus erlotinib for rash-positive metastatic pancreatic cancer patients eligible for treatment with FOLFIRINOX - a prospective phase II trial of the "Arbeitsgemeinschaft Internistische Onkologie" - AIO. In: Oncology Research and Treatment, Vol. 40: pp. 207-208

Geissler, M.; Martens, U. M.; Knorrenschield, R.; Greeve, J.; Florschütz, A.; Tannapfel, A.; Wessendorf, S.; Seufferlein, T.; Kanzler, S.; Heinemann, V.; Held, S.; Reinacher-Schick, A. (2017): mFOLFOXIRI plus panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO-KRK0109). In: Annals of Oncology, Vol. 28

Modest, Dominik P.; Ricard, Ingrid; Heinemann, Volker; Hegewisch-Becker, S.; Schmiegel, W.; Porschen, R.; Stintzing, Sebastian; Graeven, U.; Arnold, D.; Fischer von Weikersthal, L.; Giessen-Jung, Clemens; Stahler, A.; Schmoll, H. J.; Jung, A.; Kirchner, T.; Tannapfel, A.; Reinacher-Schick, A. (September 2016): Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. In: Annals of Oncology, Vol. 27, No. 9: pp. 1746-1753 [PDF, 410kB]

Giessen, C.; Graeven, U.; Laubender, Rüdiger P.; Modest, D. P.; Schulz, C.; Porschen, R.; Schmiegel, W.; Reinacher-Schick, A.; Hegewisch-Becker, S.; Stintzing, S.; Heinemann, V. (2013): Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group. In: Annals of Oncology, Vol. 24, No. 12: pp. 3051-3055

Modest, D. P.; Reinacher-Schick, A.; Stintzing, S.; Giessen, C.; Tannapfel, A.; Laubender, Rüdiger P.; Brodowicz, T.; Knittelfelder, R.; Vrbanec, D.; Schmiegel, W.; Heinemann, V.; Zielinski, C. C. (2012): Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis. In: Anticancer Drugs, Vol. 23, No. 6: pp. 666-673

This list was generated on Fri Nov 15 06:02:35 2019 CET.